{
    "organizations": [],
    "uuid": "e9feb786a58809d6eecaed0e04917fd10cfcff5d",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/19/business-wire-kala-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-host-conference-call.html",
    "ord_in_thread": 0,
    "title": "Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "WALTHAM, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will release fourth quarter and full year 2017 financial results on Monday, March 26, 2018. Kala will host a live conference call and webcast at 8:00 AM ET to provide a general business update and discuss the Company’s 2017 financial results.\nThe dial-in numbers to access the conference call are 866-300-4091 for domestic callers and 703-736-7433 for international callers. The conference ID is 7082747. To access a live webcast and subsequent archived recording of the call, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/ .\nAbout Kala Pharmaceuticals, Inc.\nKala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180319005365/en/\nInvestors and Media :\nMacDougall Biomedical Communications\nCammy Duong, 781-591-3443\ncduong@macbiocom.com\nSource: Kala Pharmaceuticals, Inc.",
    "published": "2018-03-19T15:00:00.000+02:00",
    "crawled": "2018-03-19T16:47:57.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "waltham",
        "business",
        "wire",
        "kala",
        "pharmaceutical",
        "nasdaq",
        "kala",
        "biopharmaceutical",
        "company",
        "focused",
        "development",
        "commercialization",
        "product",
        "candidate",
        "using",
        "proprietary",
        "particle",
        "mpp",
        "technology",
        "today",
        "announced",
        "release",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "monday",
        "march",
        "kala",
        "host",
        "live",
        "conference",
        "call",
        "webcast",
        "et",
        "provide",
        "general",
        "business",
        "update",
        "discus",
        "company",
        "financial",
        "result",
        "number",
        "access",
        "conference",
        "call",
        "domestic",
        "caller",
        "international",
        "caller",
        "conference",
        "id",
        "access",
        "live",
        "webcast",
        "subsequent",
        "archived",
        "recording",
        "call",
        "please",
        "visit",
        "investor",
        "medium",
        "section",
        "kala",
        "website",
        "http",
        "kala",
        "pharmaceutical",
        "kala",
        "biopharmaceutical",
        "company",
        "focused",
        "development",
        "commercialization",
        "therapeutic",
        "using",
        "proprietary",
        "particle",
        "mpp",
        "technology",
        "initial",
        "focus",
        "treatment",
        "eye",
        "disease",
        "kala",
        "applied",
        "mpp",
        "technology",
        "corticosteroid",
        "designed",
        "ocular",
        "application",
        "resulting",
        "two",
        "lead",
        "product",
        "candidate",
        "product",
        "candidate",
        "treatment",
        "inflammation",
        "pain",
        "following",
        "ocular",
        "surgery",
        "nda",
        "accepted",
        "review",
        "fda",
        "temporary",
        "relief",
        "sign",
        "symptom",
        "dry",
        "eye",
        "disease",
        "view",
        "source",
        "version",
        "http",
        "investor",
        "medium",
        "macdougall",
        "biomedical",
        "communication",
        "cammy",
        "duong",
        "cduong",
        "source",
        "kala",
        "pharmaceutical",
        "inc"
    ]
}